St James Investment Company Has Boosted Sanofi (SNY) Holding By $1.03 Million; Last Week Eli Lilly and Co (LLY) Coverage

August 29, 2017 - By test

St James Investment Company Llc increased Sanofi (SNY) stake by 1.84% reported in 2016Q4 SEC filing. St James Investment Company Llc acquired 25,708 shares as Sanofi (SNY)’s stock rose 14.25%. The St James Investment Company Llc holds 1.42 million shares with $57.62M value, up from 1.40M last quarter. Sanofi now has $124.40 billion valuation. The stock increased 0.63% or $0.31 during the last trading session, reaching $49.02. About shares traded. Sanofi SA (ADR) (NYSE:SNY) has risen 26.96% since August 29, 2016 and is uptrending. It has outperformed by 10.26% the S&P500.

Among 19 analysts covering Eli Lilly and Company (NYSE:LLY), 13 have Buy rating, 1 Sell and 5 Hold. Therefore 68% are positive. Eli Lilly and Company had 67 analyst reports since July 23, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Tuesday, December 8 by Credit Suisse. Atlantic Securities initiated it with “Overweight” rating and $100 target in Friday, December 18 report. Leerink Swann maintained the shares of LLY in report on Monday, December 28 with “Outperform” rating. The stock has “Market Perform” rating by Leerink Swann on Wednesday, July 26. Morgan Stanley upgraded Eli Lilly and Co (NYSE:LLY) on Friday, December 16 to “Overweight” rating. BMO Capital Markets maintained it with “Sell” rating and $7300 target in Tuesday, July 25 report. The firm has “Outperform” rating given on Monday, November 16 by BMO Capital Markets. The firm has “Outperform” rating given on Monday, May 2 by Leerink Swann. BMO Capital Markets downgraded Eli Lilly and Co (NYSE:LLY) rating on Friday, November 25. BMO Capital Markets has “Market Perform” rating and $64 target. The rating was upgraded by Goldman Sachs on Tuesday, September 27 to “Buy”. See Eli Lilly and Co (NYSE:LLY) latest ratings:

24/08/2017 Broker: Jefferies Rating: Buy New Target: $89.0 Maintain
16/08/2017 Broker: BMO Capital Markets Rating: Sell New Target: $73.0 Maintain
03/08/2017 Broker: Berenberg Rating: Buy New Target: $98.0000
04/08/2017 Broker: BMO Capital Markets Rating: Sell New Target: $73.0000 Maintain
26/07/2017 Broker: UBS Rating: Hold New Target: $85.0000
26/07/2017 Broker: Leerink Swann Old Rating: Outperform New Rating: Market Perform Downgrade
25/07/2017 Broker: BMO Capital Markets Rating: Sell New Target: $73.0000 Maintain
21/07/2017 Broker: Credit Suisse Rating: Buy New Target: $89.0000
19/07/2017 Broker: BMO Capital Markets Rating: Sell New Target: $73.0000 Maintain
17/07/2017 Broker: Deutsche Bank Rating: Buy Old Target: $90 New Target: $91 Maintain

St James Investment Company Llc decreased Berkley W R Corp (NYSE:WRB) stake by 62,274 shares to 989,326 valued at $65.80 million in 2016Q4. It also reduced Ishares Tr (SHY) stake by 4,475 shares and now owns 99,005 shares. Bank New York Mellon Corp (NYSE:BK) was reduced too.

Among 10 analysts covering Sanofi-aventis Sa (NYSE:SNY), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Sanofi-aventis Sa had 16 analyst reports since October 15, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Wednesday, April 12 by JP Morgan. The stock of Sanofi SA (ADR) (NYSE:SNY) has “Hold” rating given on Tuesday, May 3 by HSBC. The company was downgraded on Monday, November 9 by Bernstein. JP Morgan maintained Sanofi SA (ADR) (NYSE:SNY) on Friday, April 21 with “Neutral” rating. On Monday, November 7 the stock rating was initiated by Goldman Sachs with “Neutral”. The stock has “Neutral” rating by BNP Paribas on Tuesday, September 13. The stock has “Overweight” rating by Barclays Capital on Thursday, May 12. HSBC downgraded the shares of SNY in report on Friday, April 7 to “Reduce” rating. As per Friday, September 23, the company rating was initiated by Piper Jaffray. On Thursday, September 8 the stock rating was upgraded by Berenberg to “Buy”.

Investors sentiment decreased to 0.9 in Q4 2016. Its down 0.08, from 0.98 in 2016Q3. It turned negative, as 84 investors sold Eli Lilly and Co shares while 380 reduced holdings. 103 funds opened positions while 348 raised stakes. 809.72 million shares or 0.51% more from 805.63 million shares in 2016Q3 were reported. Roosevelt Investment Gp has 3,131 shares. 2,844 are held by Interocean Cap Limited Liability Corp. Weaver C Barksdale And Assoc Inc has invested 0.18% of its portfolio in Eli Lilly and Co (NYSE:LLY). 443,217 were reported by First Republic Investment Mngmt. Boyd Watterson Asset Management Ltd Oh has invested 0.47% in Eli Lilly and Co (NYSE:LLY). Brookfield Asset holds 0.01% or 20,770 shares in its portfolio. Mngmt Of Virginia Ltd Company invested in 0.21% or 12,210 shares. Archford Cap Strategies Limited Liability Corp reported 12,730 shares. Tradition Capital Mgmt Ltd has 12,083 shares for 0.3% of their portfolio. Benjamin F Edwards & stated it has 7,893 shares or 0.1% of all its holdings. Loring Wolcott Coolidge Fiduciary Ltd Liability Partnership Ma holds 0.01% or 4,400 shares in its portfolio. Visionary Asset has 1.09% invested in Eli Lilly and Co (NYSE:LLY). Moreover, Nationwide Fund Advsr has 0.34% invested in Eli Lilly and Co (NYSE:LLY) for 1.12M shares. Schroder Inv Mgmt Grp accumulated 1.13M shares. Moreover, Palisade Asset Ltd Llc has 0.31% invested in Eli Lilly and Co (NYSE:LLY) for 21,759 shares.

Since March 30, 2017, it had 0 insider buys, and 4 selling transactions for $21.83 million activity. LILLY ENDOWMENT INC had sold 210,000 shares worth $17.78 million on Thursday, March 30. The insider Barnes Melissa S sold 1,900 shares worth $153,482. Conterno Enrique A sold 25,000 shares worth $2.07M. The insider Harrington Michael J sold 22,833 shares worth $1.83 million.

Eli Lilly and Company is engaged in drug manufacturing business. The company has market cap of $86.80 billion. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. It has a 34.17 P/E ratio. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

The stock increased 0.06% or $0.05 during the last trading session, reaching $78.84. About shares traded. Eli Lilly and Co (NYSE:LLY) has risen 4.70% since August 29, 2016 and is uptrending. It has underperformed by 12.00% the S&P500.